Statins represent the cornerstone of pharmacotherapy for the prevention of atherosclerotic
cardiovascular disease. These medications not only reduce low-density lipoprotein …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

The development of atherosclerosis (AS) is closely linked to changes in the plaque
microenvironment, which consists primarily of the cells that form plaque and the associated …

Background Obicetrapib, a novel, selective cholesteryl ester transfer protein (CETP)
inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), LDL particles, apolipoprotein …

Statin-associated muscle symptoms (SAMS) are the most common form of statin intolerance
and are associated with increased risk of cardiovascular events that manifest from statin …

The objective of this scientific statement is to evaluate contemporary evidence that either
supports or refutes the conclusion that aggressive low-density lipoprotein cholesterol …

Reducing low-density lipoprotein cholesterol (LDL-C) levels is a key target for lowering
cardiovascular risk and preventing atherosclerotic cardiovascular disease (ASCVD). Red …

Familial hypercholesterolaemia (FH) is a common autosomal semi-dominant and highly
penetrant disorder of the low-density lipoprotein (LDL) receptor pathway, characterised by …

Abstract Purpose of Review Familial hypercholesterolemia (FH) and hyperlipoproteinemia
(a) are relatively common disorders, posing a significant health burden due to increased risk …

Statin therapy has been shown to have a significant effect on lowering of low-density
lipoprotien cholesterol (LDL-C) levels. This subsequently results in cardiovascular (CV) …